Incyte (INCY) Other Non-Current Assets (2010 - 2026)
Incyte posted quarterly Other Non-Current Assets of $1.8 million for Q1 2026, up 10.27% year-on-year from $1.7 million in Q1 2025, and down 89.89% on a QoQ basis from $18.2 million in Q4 2025.
Incyte (INCY) has 16 years of Other Non-Current Assets data on file, last reported at $1.8 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 10.27% year-over-year to $1.8 million; the trailing twelve-month figure through Mar 2026 stood at $1.8 million (up 10.27% YoY), and the FY2025 full-year result was $18.2 million, up 1019.98% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $1.8 million, down from $18.2 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $81.0 million in Q3 2023 and bottomed at $1.6 million in Q4 2024.
- The 5-year median for Other Non-Current Assets is $1.8 million (2023), against an average of $17.5 million.
- The widest annual swing landed in 2022, when Other Non-Current Assets sank 95.45%; it then soared 1895.83% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $1.7 million in 2022, then increased by 8.66% to $1.8 million in 2023, then declined by 12.09% to $1.6 million in 2024, then surged by 1019.98% to $18.2 million in 2025, then tumbled by 89.89% to $1.8 million in 2026.
- The last three Other Non-Current Assets figures came in at $1.8 million (Q1 2026), $18.2 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn | 1.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.84 Mn |
| Dec 31, 2025 | 18.17 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Jun 30, 2025 | 32.55 Mn |
| Mar 31, 2025 | 1.67 Mn |
| Dec 31, 2024 | 1.62 Mn |
| Sep 30, 2024 | 40.38 Mn |
| Jun 30, 2024 | 1.63 Mn |
| Mar 31, 2024 | 1.63 Mn |
| Dec 31, 2023 | 1.85 Mn |
| Sep 30, 2023 | 80.96 Mn |
| Jun 30, 2023 | 31.71 Mn |
| Mar 31, 2023 | 1.72 Mn |
| Dec 31, 2022 | 1.70 Mn |
| Sep 30, 2022 | 23.67 Mn |
| Jun 30, 2022 | 23.01 Mn |
| Mar 31, 2022 | 31.42 Mn |
| Dec 31, 2021 | 37.30 Mn |
| Sep 30, 2021 | 24.79 Mn |
| Jun 30, 2021 | 20.45 Mn |
| Mar 31, 2021 | 38.81 Mn |
| Dec 31, 2020 | 39.40 Mn |
| Sep 30, 2020 | 53.11 Mn |
| Jun 30, 2020 | 53.27 Mn |
| Mar 31, 2020 | 61.78 Mn |
| Dec 31, 2019 | 49.43 Mn |
| Jun 30, 2019 | 36.61 Mn |
| Mar 31, 2019 | 20.70 Mn |
| Dec 31, 2018 | 19.16 Mn |
| Sep 30, 2018 | 14.67 Mn |
| Jun 30, 2018 | 10.73 Mn |
| Mar 31, 2018 | 9.88 Mn |
| Dec 31, 2017 | 2.22 Mn |
| Sep 30, 2017 | 7.03 Mn |
| Jun 30, 2017 | 3.23 Mn |
| Mar 31, 2017 | 543,000.00 |
| Dec 31, 2016 | 2.64 Mn |
| Sep 30, 2016 | 2.56 Mn |
| Jun 30, 2016 | 2.50 Mn |
| Dec 31, 2015 | 12.28 Mn |
| Jun 30, 2015 | 14.26 Mn |
| Mar 31, 2015 | 13.88 Mn |
| Dec 31, 2014 | 14.00 Mn |
| Sep 30, 2014 | 14.13 Mn |
| Jun 30, 2014 | 14.25 Mn |
| Mar 31, 2014 | 14.38 Mn |
| Dec 31, 2013 | 14.50 Mn |
| Sep 30, 2011 | 8.74 Mn |
| Jun 30, 2011 | 9.27 Mn |
| Mar 31, 2011 | 18.91 Mn |
| Dec 31, 2010 | 18.89 Mn |